Another national patent granted

The new national patent “Salophene iron complexes with heterocyclic N-donor ligands, process of their preparation and their use as medicaments in antitumor therapy” (CZ 304883, granted on 2014/11/12), protects the industrial applicability of iron(II/III) complexes, involving the combination of ligands, i.e. the N,N’-bis(salicylidene)-1,2-phenylenediamine (salophen) and small monodentate N-donor heterocyclic ligands of the substituted azole-type, as promising anticancer drugs with high antiproliferative effect, surpassing the activity of therapeutically used anticancer drug – cisplatin up to 200-times. The high effectiveness of the complexes was proved by the results of testing on the broad panel of human cancer cell lines.